N/A N=30 Music Therapy in Sickle Cell Transition Study
Sickle Cell Disease
Primary: Change (T1 - T5) From Baseline in Scores on the Sickle Cell Self-Efficacy Scale (SCSES) — -1.73 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=372 Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
Obesity
Primary: Body Weight — -28.35; -23.95 Pounds — p=<0.0001
N/A N=93 Educational Video and Peri-operative Anxiety
Ambulatory Surgical Procedures · Anxiety Disorders
Primary: VAS-A Score Anxiety Level (Adapted Visual-Analogue Scale) — 1.22; 1.02 score on a scale
Phase 1 N=6 Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants
Healthy Volunteers
Primary: Percentage of Urinary and Fecal Excretion of LY2886721 Radioactivity Over Time — 85.7; 8.86 percentage of radioactive dose
Phase 2 N=289 The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study
Inflammation
Primary: Changes in the Interleukin-6 Level Between Groups — 0; -0.1; -0.6; 3.8 pg/ml
N/A N=200 Postoperative Intermittent Intrauterine Balloon Dilatation Therapy.
Intrauterine Adhesion
Primary: Number of Participants With Adhesion Reformation (American Fertility Society Score of Greater Than 0) 8 Weeks Later After the Index Surgery — 21; 38 Participants — p=0.012
N/A N=80 Video-Enhanced Care Management for Medically Complex Veterans
Multimorbidity · Cognitive Impairments
Primary: Number of Participants Reporting That They Would Be Likely to See a Healthcare Provider Using Videochat — 6; 5 Participants
Phase 2 N=70 Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Rhinitis
Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale
Phase 1 N=24 PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women
Female Sexual Dysfunction
Primary: Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles — 223.981; 328.002; 834.391; 553.325 ng*h/dL
Phase 3 N=770 Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Breast Cancer
Primary: Progression Free Survival — 5.6; 4.3 Months — p=0.0426
N/A N=49 Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly Sheffield)
Neonatal Neuroimaging
Primary: Image Diagnostic Quality for Phase 1 — 24 Participants
N/A N=529 The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
Hepatitis C · Drug Users · Harm Reduction
Primary: Percentage of HCV Infected Paticipants Whom Result of the Test Was Delivered to — 101 Participants
Phase 2 N=35 Obeticholic Acid in Bile Acid Diarrhoea
Primary Bile Acid Malabsorption · Secondary Bile Acid Malabsorption · Chronic Diarrhoea
Primary: Changes in Fasting FGF19 — 71; 25; 130 percentage increase of baseline — p=0.007
N/A N=21 Physical Activity and Gastrointestinal Investigations
Gastro-oesophageal Reflux Disease
Primary: Physical Activity Change (%) — -22 Percentage change in activity
N/A N=90 Treatment of Social Anxiety Disorder and Selective Mutism
Social Anxiety Disorder · Selective Mutism
Primary: Change in Clinical Severity Ratings (CSR) of SAD & SM on the Anxiety Disorders Interview Schedule - Parent Version (ADIS-P) — -1.26; -1.65; -1.51; -1.24 units on a scale…